Login to Your Account



Gamida Cell's StemEx Improves Overall Survival in Phase II/III

By Marie Powers
Staff Writer

Wednesday, February 6, 2013
Israeli biotech Gamida Cell Ltd. moved lead product StemEx one step closer to becoming potentially the first allogeneic biologic cell product to achieve marketing approval in the U.S. and Europe. The therapy, which uses the company's copper chelator technology, demonstrated overall survival – the primary endpoint – in a Phase II/III study comparing its use in a transplantation regimen to historical controls when treating patients with hematologic malignancies such as leukemia and lymphoma who could not find a family-related matched bone marrow donor following myeloablative therapy.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription